These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 39293087)
21. Influence of anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection: a multicenter retrospective study. Tomida H; Yoshio T; Igarashi K; Morita Y; Oda I; Inoue T; Hikichi T; Sumiyoshi T; Doyama H; Tsuji Y; Nishikawa J; Hatta W; Mikami T; Iguchi M; Sumiyama K; Yamamoto K; Kitamura K; Kuribayashi S; Yanagitani A; Uraoka T; Yada T; Hasatani K; Kawaguchi K; Fujita T; Nishida T; Hiasa Y; Fujishiro M; Gastric Cancer; 2021 Jan; 24(1):179-189. PubMed ID: 32683602 [TBL] [Abstract][Full Text] [Related]
22. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319 [TBL] [Abstract][Full Text] [Related]
23. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868 [TBL] [Abstract][Full Text] [Related]
24. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis. Mainbourg S; Cucherat M; Provencher S; Bertoletti L; Nony P; Gueyffier F; Mismetti P; Grange C; Durieu I; Kilo R; Laporte S; Grenet G; Lega JC; Thromb Res; 2021 Jan; 197():24-32. PubMed ID: 33161284 [TBL] [Abstract][Full Text] [Related]
25. Challenges and Possible Solutions to Direct-Acting Oral Anticoagulants (DOACs) Dosing in Patients with Extreme Bodyweight and Renal Impairment. Nwanosike EM; Sunter W; Merchant HA; Conway BR; Ansari MA; Hasan SS Am J Cardiovasc Drugs; 2023 Jan; 23(1):9-17. PubMed ID: 36515822 [TBL] [Abstract][Full Text] [Related]
26. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. Weitz JI; Jaffer IH; Fredenburgh JC F1000Res; 2017; 6():985. PubMed ID: 28713563 [TBL] [Abstract][Full Text] [Related]
27. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis. Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871 [TBL] [Abstract][Full Text] [Related]
28. Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence. Willett KC; Morrill AM Ther Clin Risk Manag; 2017; 13():447-454. PubMed ID: 28435279 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. Hindley B; Lip GYH; McCloskey AP; Penson PE Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):911-923. PubMed ID: 37991392 [TBL] [Abstract][Full Text] [Related]
30. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697 [TBL] [Abstract][Full Text] [Related]
31. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. Leung TS; Law EH Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422 [TBL] [Abstract][Full Text] [Related]
32. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. Miyazaki M; Matsuo K; Uchiyama M; Nakamura Y; Sakamoto Y; Misaki M; Tokura K; Jimi S; Okamura K; Adachi S; Yamamoto T; Shirai K; Urata H; Imakyure O J Pharm Health Care Sci; 2020; 6():2. PubMed ID: 32071730 [TBL] [Abstract][Full Text] [Related]
33. Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants. Abdrakhmanov A; Shaimerdinova A; Suleimen Z; Abildinova S; Albayev R; Tuyakova G; Rib E; Beysenbayeva A; Kabduyeva G; Bekbossynova M Ther Adv Cardiovasc Dis; 2024; 18():17539447241249886. PubMed ID: 38801157 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Sharma M; Cornelius VR; Patel JP; Davies JG; Molokhia M Circulation; 2015 Jul; 132(3):194-204. PubMed ID: 25995317 [TBL] [Abstract][Full Text] [Related]
35. Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data. Diesveld MME; Pijnenburg DWMJ; Weersink RA; Barzel I; Drenth JPH; Lisman T; Metselaar HJ; Monster-Simons MH; Mulder MB; Okel E; Taxis K; Borgsteede SD Eur J Clin Pharmacol; 2024 Jun; 80(6):797-812. PubMed ID: 38430266 [TBL] [Abstract][Full Text] [Related]
36. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts. Bazarbashi S; El Zawahry HM; Owaidah T; AlBader MA; Warsi A; Marashi M; Dawoud E; Jaafar H; Sholkamy SM; Haddad F; Cohen AT J Blood Med; 2024; 15():171-189. PubMed ID: 38686358 [TBL] [Abstract][Full Text] [Related]
37. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. Weitz JI; Jaffer IH Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622 [TBL] [Abstract][Full Text] [Related]
38. Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF. Guenoun M; Cohen S; Villaceque M; Sharareh A; Schwartz J; Hoffman O; Dib JC; Ouazana L; Assouline S; Parrens E; Garban T; Pradeau V; Guedj-Meynier D; Lequeux B; Cohen C; Durand P; Dievart F; Dhanjal TS; Sabouret P; Lellouche N Europace; 2023 Oct; 25(10):. PubMed ID: 37801642 [TBL] [Abstract][Full Text] [Related]
39. Baseline Characteristics and 3-Year Outcome of Nonvalvular Atrial Fibrillation Patients Treated with the Four Direct Oral Anticoagulants (DOACs). Nemola G; Russi A; Cozzani G; Leo G; Vetrugno L; Sparasci FM; Parlati AL; Della Bella P; Montorfano M; Tresoldi M; Salerno A; Cera M; Mattiello P; Comi G; Maisano F; Zangrillo A; Gaspardone C; Melillo F; Margonato A; Godino C; Am J Cardiol; 2023 Nov; 206():125-131. PubMed ID: 37703678 [TBL] [Abstract][Full Text] [Related]
40. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials. Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]